Notable Mover: XBiotech Inc Declines Again; Strong Momentum for Sellers

Notable Mover: XBiotech Inc Declines Again; Strong Momentum for Sellers

The stock of XBiotech Inc (NASDAQ:XBIT) is a huge mover today! About 62,275 shares traded hands. XBiotech Inc (NASDAQ:XBIT) has risen 12.74% since April 18, 2016 and is uptrending. It has outperformed by 8.31% the S&P500.
The move comes after 7 months negative chart setup for the $540.59 million company. It was reported on Nov, 18 by We have $14.57 PT which if reached, will make NASDAQ:XBIT worth $37.84 million less.

According to Zacks Investment Research, “XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States.”

More recent XBiotech Inc (NASDAQ:XBIT) news were published by: which released: “Why XBiotech Inc. Fell 33% Today” on July 05, 2016. Also published the news titled: “XBiotech Inc. NASDAQ: XBIT” on April 15, 2015.‘s news article titled: “Why XBiotech Inc. Made a U-Turn Today” with publication date: December 08, 2015 was also an interesting one.

XBIT Company Profile

XBiotech Inc., incorporated on October 23, 2005, is a clinical-stage biopharmaceutical company. The Firm is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Firm focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Firm has also developed a True Human monoclonal antibody discovery platform and manufacturing system. The Company’s therapeutic antibody, Xilonix, is being evaluated as a monotherapy to treat advanced stages of colorectal cancer. Xilonix neutralizes a pro-inflammatory protein produced by leukocytes and other cells, interleukin-1 alpha (IL-1a).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment